The Latest Life Sciences Tools & Diagnostics Articles from Streetwise Reports


MRI Device Maker's Earnings Come In at High End of Forecasts

Research Report
  ()
IRadimed Corp. reported Q2/22 financial results that were modestly higher than expected. ROTH Capital Partners LLC advised in a research update that based on the company's higher revenues, improved margins, and disciplined cost control measures it is maintaining its Buy rating on IRadimed and raising its price target to $42/share (up from $40).

Monkeypox Virus Test Could Yield Revenue for Its Creator

Research Report
  ()
The Utah-based diagnostics firm has multiple shots on goal with this specific molecular test and with its convenient, fast testing platform, both in development, noted an H.C. Wainwright & Co. report.

Is Reliq Health Technologies a Nutrimental 'Buy'?

Contributed Opinion
  ()
After recovering from a short "character assassination," Reliq Health Technologies may be on the up-and-up. Clive Maund examines the latest data from the company to see if it would make a good 'buy'.

Co. to Rebound After Q4/21 Sales Down Due to Virus Surge

Research Report
  ()
The 2022 outlook for a cancer detection and therapy solutions company is positive given its focus on dermatology and implementing new commercial strategies, noted an Oppenheimer report.

Showing Results: 1 to 9 of 9

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts